Skip to main content

Argenica Therapeutics Health Care
Biotech Healthcare

$0.375 0.005 (1.35%)

High

$0.38

Low

$0.38

Trades

2

Turnover

$1,293

Volume

3,448
30 June 2023 at 10:43am
If you were already registered, log in here.

Short Interest

ASIC data, 3 Jul 2026

% Shorted

0.01% 0.01
vs 0.00% prior report

Most Shorted Rank

627th
of 711 shorted ASX stocks

Peak Short

0.01%
Jul 2026

Days to Cover

0.2
at 50d avg vol
View full short position history →
Subject
StockBot
AGN Ann: ARG-007 Protects Brain Cells in Moderate TBI Model

StockBot
AGN Ann: Becoming a substantial holder

StockBot
AGN Ann: Becoming a substantial holder

StockBot
AGN Ann: Application for quotation of securities - AGN

StockBot
AGN Ann: Notification regarding unquoted securities - AGN

StockBot
AGN Ann: Cleansing Notice

StockBot
AGN Ann: Application for quotation of securities - AGN

StockBot
AGN Ann: Release of Restricted Securities From Escrow

StockBot
AGN Ann: Proposed issue of securities - AGN

StockBot
AGN Ann: Argenica Successfully Completes $4.0m Placement

StockBot
AGN Ann: Trading Halt

StockBot
AGN Ann: Final Phase1 Clinical Trial Report

StockBot
AGN Ann: Quarterly Activities/Appendix 4C Cash Flow Report

StockBot
AGN Ann: Latest Preclinical HIE Study Results

StockBot
AGN Ann: Significant Non-Dilutive Funding For Preclinical HIE Studies

StockBot
AGN Ann: Interim Phase 1 Safety Report Confirms Safety of ARG-007

StockBot
AGN Ann: Half Yearly Report and Accounts

StockBot
AGN Ann: Non-Dilutive Funding Received to Progress Alzheimers Studies

StockBot
AGN Ann: Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers

StockBot
AGN Ann: Investor Presentation

StockBot
AGN Ann: Quarterly Activities/Appendix 4C Cash Flow Report

StockBot
AGN Ann: Argenica Awarded $1.2m CRC-P Grant for TBI Project

StockBot
AGN Ann: Successful Completion of Phase 1 Clinical Trial Dosing

StockBot
AGN Ann: Ceasing to be a substantial holder

StockBot
AGN Ann: SRC Approves Commencement Of Fourth And Final Cohort Dosing

StockBot
AGN Ann: Change of Director's Interest Notice

StockBot
AGN Ann: Notification regarding unquoted securities - AGN

StockBot
AGN Ann: Phase 1 Clinical Trial Progress Update

StockBot
AGN Ann: AGM Presentation

StockBot
AGN Ann: Results of Annual General Meeting

StockBot
AGN Ann: Safety Review Committee Approves Third Cohort Commencement

StockBot
AGN Ann: Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial

StockBot
AGN Ann: Safety Review Committee Approves Second Cohort

StockBot
AGN Ann: Quarterly Activities/Appendix 4C Cash Flow Report

StockBot
AGN Ann: No Serious Safety Issues Observed in First Cohort

StockBot
AGN Ann: Notice of Annual General Meeting/Proxy Form

StockBot
AGN Ann: Investor Presentation

StockBot
AGN Ann: First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007

StockBot
AGN Ann: Argenica Receives $1.38m R&D Tax Incentive Cash Refund

StockBot
AGN Ann: Further Positive Preclinical Results for ARG-007 In HIE

StockBot
AGN Ann: Date of AGM and Closing Date for Director Nominations

StockBot
AGN Ann: Phase 1 Clinical Trial Summary

StockBot
AGN Ann: Argenica Receives Ethics Approval To Commence Phase 1 Trial

StockBot
AGN Ann: Appendix 4G & Corporate Governance Statement

StockBot
AGN Ann: Appendix 4E & Annual Report 30 June 2022

StockBot
AGN Ann: Ethics Application Submitted for Phase 1 Trial

StockBot
AGN Ann: Quarterly Activities/Appendix 4C Cash Flow Report

StockBot
AGN Ann: Clinical Advisory Committee Appointment

StockBot
AGN Ann: Notification regarding unquoted securities - AGN

StockBot
AGN Ann: Peer Reviewed Paper Published on Preclinical Safety Study

If you were already registered, log in here.

Upcoming Floats (8)

MATRIX CRITICAL MINERALS LIMITED
MTX
SUPER MINERALS LTD
S88
MAVERICK URANIUM LIMITED
MAV
Fitgenes
ATW $7.5m raise
RIO DE ORO CORP LTD
RDO $30m raise
Adbri Ltd
ABC $5m raise
RAMSAY GENERALE DE SANTE SA
RGS
Gratifii
MBM
Top